索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]陈长源,张钲.高密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病[J].国际心血管病杂志,2015,05:326-328.
点击复制

高密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2015年05期
页码:
326-328
栏目:
综述
出版日期:
2015-09-25

文章信息/Info

Title:
-
作者:
陈长源; 张钲
730000 兰州大学第一医院心内科
Author(s):
-
关键词:
高密度脂蛋白胆固醇; 胆固醇外排能力; 动脉粥样硬化性心血管疾病
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2015.05.009
文献标识码:
-
摘要:
血高密度脂蛋白胆固醇(HDL-C)水平与动脉粥样硬化性心血管疾病(ASCVD)发生、发展相关,然而提高患者血浆HDL-C水平的药物未能降低ACSVD风险。研究发现,HDL-C亚类HDL3-C以及HDL-C的胆固醇外排能力(CEC)在ASCVD发生、发展过程中对心脏起重要保护作用,这为预测心血管事件风险及指导调脂治疗策略提供了新思路。
Abstract:
-

参考文献/References

[1] Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[J]. Circulation, 2014, 129(25 Suppl 2): S1-S45.
[2] AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med, 2011, 365(24): 2255-2267.
[3] HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med, 2014, 371(3): 203-212.
[4] Jensen MK, Bertoia ML, Cahill LE, et al. Novel metabolic biomarkers of cardiovascular disease[J]. Nat Rev Endocrinol, 2014, 10(11):659-672.
[5] Landmesser U. Coronary artery disease: HDL and coronary heart disease-novel insights[J]. Nat Rev Cardiol, 2014, 11(10): 559-560.
[6] Martin SS, Khokhar AA, May HT, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the lipoprotein investigators collaborative[J]. Eur Heart J, 2015, 36(1): 22-30.
[7] Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events[J]. N Engl J Med, 2014, 371(25): 2383-2393.
[8] Rizzo M, Otvos J, Nikolic D, et al. Subfractions and subpopulations of HDL: an update[J]. Curr Med Chem, 2014, 21(25): 2881-2891.
[9] Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease[J]. Trends Mol Med, 2011, 17(10): 594-603.
[10] Rosenson RS, Brewer HB Jr, Chapman MJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events[J]. Clin Chem, 2011, 57(3): 392-410.
[11] Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease[J]. J Clin Lipidol, 2012, 6(6): 496-523.
[12] 胡泽波,马坤岭. 亚细胞器在胆固醇代谢紊乱中的作用[J]. 国际心血管病杂志, 2014, 41(6): 362-364.
[13] Saleheen D, Scott R, Javad S, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study[J]. Lancet Diabetes Endocrinol, 2015,3(7):507-513.
[14] Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis[J]. N Engl J Med, 2011, 364(2): 127-135.
[15] Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks[J]. Arterioscler Thromb Vasc Biol, 2013, 33(7): 1696-1705.
[16] Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis[J]. Nat Med, 2013, 19(5): 586-594.
[17] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 367(22): 2089-2099.
[18] Martin SS, Jones SR, Toth PP. High-density lipoprotein subfractions: current views and clinical practice applications[J]. Trends Endocrinol Metab, 2014, 25(7): 329-336.
[19] Zambon A, Zhao XQ, Brown BG, et al. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease[J]. Am J Cardiol, 2014, 113(9): 1494-1498.
[20] Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group[J]. N Engl J Med, 1999, 341(6): 410-418.
[21] Rosenblat M, Volkova N, Aviram M. HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: In vivo and in vitro studies[J]. Biofactors, 2014, 40(5): 536-545.
[22] Kingwell BA, Chapman MJ, Kontush A, et al. HDL-targeted therapies progress failures and future[J]. Nat Rev Drug Discov, 2014, 13(6): 445-464.

备注/Memo

备注/Memo:
通信作者:张 钲,Email: zhangccu@163.com
更新日期/Last Update: 2015-10-20